Study S000381

Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Switching Premix Human Insulin to Aspart30 in T2DM With Inadequate Glycaemic Control on Premixed Human Insulin and Metformin: a Randomized, Open, Parallel Trial

ClinicalTrials.gov record

Registration

Registration: NCT02467920
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 349
Start: 2015-08
Primary completion: 2017-12
Lead sponsor: Huazhong University of Science and Technology
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:glargine + exenatide; DRUG:aspart 30
Results posted: FALSE

Registered primary outcomes

the absolute change in HbA1c from baseline to 24-week endpoint of basal insulin glargine combination with exenatide bid vs. switching to aspart30 in type 2 diabetic patients inadequately controlled on premixed human insulin and metformin. [from baseline to 24-week endpoint]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.